Jade Biosciences, Inc. (JBIO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
JBIO currently has 49.3M outstanding shares. with significant dilution risk as 60M authorized shares could dilute existing holders by 121.5%. The company has significantly diluted shareholders by 110.09% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
S-3 filing: This S-3 filing registers the resale of up to 39,542,339 shares of common stock by selling stockholders, including shares issued in private placements, shares issuable upon exercise of warrants, and shares issuable upon conversion of Series A Preferred Stock. |
49M | 60M |
| May 07, 2026 |
10-Q filing | 49.4M shares outstanding |
49M | 20M |
| Dec 22, 2025 |
S-1 filing: This S-1 filing registers shares of common stock for resale by a selling stockholder, as part of a registration rights agreement. |
33M | 20M |
| Nov 14, 2025 |
10-Q filing | 46.0M shares outstanding |
46M | 1.1M |
| Nov 14, 2025 |
S-1 filing: This is an S-1 filing registering resale shares for selling stockholders, including PIPE shares, shares from pre-funded warrants, and existing common stock. |
33M | 17M |
| Aug 13, 2025 |
10-Q filing | 32.6M shares outstanding |
33M | 1.1M |
| Apr 25, 2025 |
10-Q filing | 29.0M shares outstanding |
29M | 1.1M |
| Mar 27, 2025 |
10-K filing | 28.6M shares outstanding |
29M | 1.1M |
| Nov 12, 2024 |
10-Q filing | 28.9M shares outstanding |
29M | 1.1M |
| Aug 12, 2024 |
10-Q filing | 28.8M shares outstanding |
29M | 1.1M |
| Jun 10, 2024 |
S-3 filing: Aerovate Therapeutics, Inc. is filing a Form S-3 registration statement to register an offering of up to $350,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. |
28M | 1.1M |
| May 13, 2024 |
10-Q filing | 27.8M shares outstanding |
28M | 1.1M |
| Mar 25, 2024 |
10-K filing | 26.3M shares outstanding |
26M | 1.1M |
| Nov 13, 2023 |
10-Q filing | 27.6M shares outstanding |
28M | 1.1M |
| Aug 14, 2023 |
10-Q filing | 25.2M shares outstanding |
25M | 1.1M |
| May 15, 2023 |
10-Q filing | 24.8M shares outstanding |
25M | 1.1M |
| Mar 29, 2023 |
10-K filing | 24.5M shares outstanding |
24M | 1.1M |
| Nov 14, 2022 |
10-Q filing | 24.5M shares outstanding |
24M | 1.1M |
| Aug 15, 2022 |
10-Q filing | 24.4M shares outstanding |
24M | 1.1M |
| Aug 15, 2022 |
S-3 filing: Aerovate Therapeutics, Inc. files an S-3 to offer up to $300,000,000 in aggregate principal amount of common stock, preferred stock, debt securities, warrants and/or units. The common stock is traded on The Nasdaq Global Market under the symbol "AVTE." |
24M | 1.1M |
| May 16, 2022 |
10-Q filing | 24.4M shares outstanding |
24M | 1.1M |
| Mar 30, 2022 |
10-K filing | 24.4M shares outstanding |
24M | 1.1M |
| Nov 15, 2021 |
10-Q filing | 24.4M shares outstanding |
24M | 1.1M |
| Aug 16, 2021 |
10-Q filing | 0.2M shares outstanding |
240K | 1.1M |
| Jun 25, 2021 |
S-1/A filing: S-1/A filing includes the aggregate offering price of 1,072,500 additional shares that the underwriters have the option to purchase. |
14M | 1.1M |
| Jun 24, 2021 |
S-1/A filing: This S-1/A filing relates to the gain on sale, exchange, or other taxable disposition of shares of our common stock, detailing the offering of 7,150,000 shares, with an option for underwriters to purchase an additional 1,072,500 shares, and outlines the company's intended use of proceeds. |
14M | 22M |
| Jun 17, 2021 |
S-1/A filing: This S-1/A filing describes the grant of employee stock options to purchase common stock. |
N/A | 0 |